After 30 years in the cell therapy space, Dr Michael Leek founded TC BioPharm in Scotland. Within four years the company has forged major partnership deals and advanced its CAR T therapies towards the clinic. Developing allogeneic variants of Gamma Delta T Cells, TC BioPharm aims to become a global company, taking the next step of its international expansion with opening of an office in continental Europe.
Can you outline for us your personal journey and what led you to found TC BioPharm (TCB) in 2014?
"Recently, against all odds, amid the Brexit turmoil, we were awarded a EUR 4m single company grant by Horizon2020. This was instrumental in taking a decision to roll out the move from autologous to allogeneic therapies."
